shanghai synergy pharmaceutical sciences co.,ltd. was founded in August 2015. It is a wholly-owned subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd. with a registered capital of RMB70 million. The company is located at the core park of the national Shanghai Biomedicine Technology Industry Base, Zhangjiang Hi-Tech Industrial Development Zone, Shanghai. It is engaged in the R&D of small molecular and innovative medicine, mainly pertaining to the fields of cardiovascular, central nervous and tumor diseases.
As the innovative medicine R&D center of Zhejiang Huahai Pharmaceutical Co., Ltd., the company presently has a sound R&D system, senior researchers, a comprehensive new medicine R&D evaluation system and efficient innovative team. It carries out a high level of scientific research on self-developed projects and in-licensed projects. The company aims to achieve domestic top-tier innovative medicine R&D by 2025 and help Zhejiang Huahai Pharmaceutical Co., Ltd. transform and upgrade into a leading innovative medicine R&D enterprise, and form Huahai's advantages in the fields of central nervous, cardiovascular, tumor, immune and metabolic diseases.
Shanghai Huaotai Biopharmaceutical Co., Ltd. and Zhejiang Huahai Biotechnology Co., Ltd. have completed their merger. As a subsidiary of Huaotai, Zhejiang Huahai Biotechnology focuses on clinical Phase III drugs and commercial production.
Multiple project clinical trials approved (HB0025, HB0030, HB0034)
Multiple project clinical trials approved (HB0017, HOT-1030, HB0025, HB002.1M)
In January, Huaotai Bio received a drug production license
6月，华奥泰与君实药业以人民币9000万元达成转让阿瓦斯汀生物类似药合作
12月，华奥泰被认定为高新技术企业
Work Together
Innovate
Pioneering and striving for first-class social and economic benefits to promote rapid social and economic development
People-oriented, focusing on talent cultivation, providing employees with a fair, just and healthy development platform
Unity, striving,Striving for progress, surpassing
